Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $24.29.
IMMX has been the subject of several research reports. HC Wainwright raised their target price on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, October 15th. Mizuho increased their price objective on shares of Immix Biopharma from $15.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Morgan Stanley reaffirmed an “overweight” rating on shares of Immix Biopharma in a report on Tuesday. Finally, Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th.
Read Our Latest Report on Immix Biopharma
Institutional Inflows and Outflows
Immix Biopharma Trading Down 2.4%
Shares of IMMX stock opened at $8.15 on Tuesday. The stock has a 50 day moving average of $11.49 and a two-hundred day moving average of $10.20. Immix Biopharma has a 12 month low of $2.85 and a 12 month high of $15.10. The company has a market capitalization of $583.04 million, a P/E ratio of -9.26 and a beta of 0.24.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Sell-side analysts predict that Immix Biopharma will post -0.76 earnings per share for the current fiscal year.
About Immix Biopharma
Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company’s research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.
Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.
Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.
Further Reading
- Five stocks we like better than Immix Biopharma
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
